JHJessica M. Haddad

Jessica M. Haddad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jessica M. Haddad has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • College Mental Health

    by Jessica Haddad, Meera Menon, Rachel Conrad

  • Responding to Suicide in School Communities: An Examination of Postvention Guidance from Expert Recommendations and Empirical Studies

    by James Aluri, Jessi M. Haddad, Susan Parke, Victor Schwartz, Shashank V. Joshi, Meera Menon, Rachel C. Conrad

    Purpose of Review We review the published literature on a school’s response after a student dies by suicide (“postvention”). We examine published recommendations based on expert guidance and empirical studies that have evaluated postvention measures. Recent Findings Experts recommend careful communication with family, staff, and students that adheres to published suicide reporting guidelines. Experts also emphasize the importance of identifying and supporting high-risk students. Few robust, controlled studies have identified effective postvention measures. Effective measures tended to occur in group settings (e.g., group therapy), focus on improving grief symptoms, and involve mental health professionals. Summary Postvention has not been robustly studied in the school context. Expert recommendations and a few evidence-backed studies provide the frame for a coherent, school-based postvention response. Further research is needed to strengthen and expand our collective understanding of effective postvention measures in the school context as youth suicide attempts continue to rise.


  • The Impact of Social Media on College Mental Health During the COVID-19 Pandemic: a Multinational Review of the Existing Literature

    by Jessica M. Haddad, Christina Macenski, Alison Mosier-Mills, Alice Hibara, Katherine Kester, Marguerite Schneider, Rachel C. Conrad, Cindy H. Liu

    Purpose of Review During the COVID-19 pandemic, both social media use and rates of anxiety and depression among college students have increased significantly. This begs the question, what is the relationship between social media use and college student mental health during the COVID-19 pandemic? Recent Findings Prior studies have found mixed results regarding the relationship between social media use and college student mental health. This relationship has become increasingly complex during the COVID-19 pandemic. We found that excessive or problematic social media use during the COVID-19 pandemic was correlated with worse mental health outcomes that could be mitigated by dialectical thinking, optimism, mindfulness, and cognitive reappraisal. Summary The COVID-19 pandemic acts as a moderator by strengthening the relationship between social media use and mental health. Future studies should consider the impact of social media on college student mental health and concentrate on intervention initiatives to ensure the psychological well-being of college students during a global pandemic outbreak.


  • Family planning in carriers of BRCA1 and BRCA2 pathogenic variants

    by Jessica M. Haddad, Katina Robison, Lindsey Beffa, Jessica Laprise, Jennifer ScaliaWilbur, Christina A. Raker, Melissa A. Clark, Erin Hofstatter, Disha Dalela, Amy Brown, et al.

    BRCA1 and BRCA2 pathogenic variant carriers have a high lifetime risk of developing breast and ovarian malignancies. Given the risks and significant ramifications of undergoing risk‐reducing surgeries, many pathogenic variant carriers unaffected by cancer (previvors) struggle with family planning and reproductive decision making. The objective of this study was to determine the attitudes and practices of BRCA1 and BRCA2 pathogenic variant carriers with respect to family planning decision making. A cross‐sectional survey was conducted of BRCA1 and BRCA2 previvors at four Northeastern medical centers. The survey was administered electronically via email using REDCap. The survey included demographic information as well as questions about genetic testing, prophylactic surgeries, family planning, and partnering. Data were analyzed with Fisher's exact tests and t tests. The survey was completed by 139 of 422 BRCA1 and BRCA2 pathogenic variant carriers (response rate 33%). Thirteen were excluded from analysis due to self‐reported cancer history. Of the remaining 126, 21 (16.7%) were male and 105 (83.3%) were female. Female participants BRCA1 and BRCA2 pathogenic variant (p < 0.0001). Younger women also reported their genetic status had a stronger impact on their romantic relationships (p = 0.029). Men were significantly more likely to report that they felt no urgency to have a family compared to women (p < 0.0001). Our study reflects the complex decision making for previvors and the intricacies of family planning in this population. Providers can use this knowledge as a guide to counsel patients about reproductive options.


  • Assessing How Violent Threats from Students Toward Schools Are Affected Before and After a School Shooting

    by Jessica Haddad, Kyle Curtis, Carmen Kilpatrick, Alison Chambers, Pamela Hoffman, Kathleen Donise


  • Integrated safety analysis of elesclomol (formerly STA-4783) co-administered with paclitaxel

    by S. S. Agarwala, J. Haddad, E. Jacobson

    14595 Background: Elesclomol is a novel small-molecule oxidative stress inducer known to synergize with taxanes and certain other chemotherapeutics. Co-administered with paclitaxel (E+P), it demonstrated encouraging activity in metastatic melanoma in a recent Phase 2 trial. Methods: Between 2003 and 2006 at >20 sites, a total of 3 Phase 1 (solid tumors) and 2 Phase 2 (melanoma, sarcoma) clinical trials of E+P were completed. Various dose regimens were explored, and 1 randomized, blinded study had a paclitaxel control. Exposure, adverse event (AE) and lab data were combined. All AE data were graded per CTCAE v.3 and re-coded to MedDRA 9.0. All treated patients (pts) were analyzed by treatment received. Results: 239 pts received E+P, with 224 receiving E at or above 213 mg/m2, the dose currently under investigation in a Phase 3 trial in metastatic melanoma. Of 269 total treated pts, 62% were male, 89% were Caucasian; mean age = 57. Mean E+P treatment duration = 85 d (range 1 to 554 d). The most frequent AEs for E+P pts were fatigue, alopecia, nausea, constipation, and diarrhea. The most frequent ≥ Grade 3 AEs are presented below; P-alone blinded control data (metastatic melanoma) are given for comparison. Lab data show a small incidence increase in ≥ Grade 3 neutropenia for the E+P group vs. P alone. The most frequent non-neoplastic AEs resulting in E+P discontinuation were hypersensitivity reactions, neuropathic events, and respiratory disorders; comparable %s of P-alone pts discontinued P for these reasons. Conclusions: Given via various dosing regimens to oncology populations, E+P demonstrated small toxicity increases over P alone and was generally well tolerated. Observed E+P toxicities were typical of taxane administration. No ≥ Grade 3 AE exceeded 10%. Slight incidence increases for ≥ Grade 3 neutropenia were observed; a small P-alone sample limits interpretation.